Navigation Links
New 'bubble' targets only cancer cells
Date:2/19/2009

For millions of Americans with cancer, the side effects of chemotherapy and other treatment drugs can be devastating. But new drug-delivery research based on nano- and microtechnology from Tel Aviv University might provide much-needed relief, as well as more effective cancer treatment.

New drug delivery technology developed by Prof. Rimona Margalit of Tel Aviv University's Department of Biochemistry allows drugs to target cancer cells specifically, leaving surrounding healthy cells intact and reducing the painful side effects of chemotherapy. The science utilizes tiny bubbles, visible only through powerful microscopes, that contain payloads of therapeutic drugs.

"This development is on the leading edge of the new frontier of drug delivery and cancer treatment," says Prof. Margalit. "Bubble technology can also be applied to other medical conditions, including diabetes, osteoarthritis, wounds, and infectious diseases. In twenty years, it could be widespread."

Target: Cancer

Currently, cancer drugs travel throughout the body delivering powerful medication to all the cells they encounter, both healthy and cancerous. When healthy cells are damaged by unnecessary medication, a patient can experience unpleasant side effects ranging from hair loss to nausea. More worrying are further health risks due to the damage that the medication does to the patient's immune system.

Called "drug carriers" recent reports of Prof. Margalit's new technology applied in both cancer and osteoarthritis therapies were published in Nature Nanotechnology, and in the Journal of Controlled Release (2008). The technology allows cancer treatment medication to be placed inside tiny bubbles so small that millions fit along a single inch. The surface of the bubbles contains an agent that allows them distinguish cancer cells from healthy ones. When the bubbles "recognize" a cancer cell, they deliver the medication they're carrying to that cell.

The positive results are twofold: More of the drug gets directly to the cancer cells, enhancing the effectiveness of the treatment, and healthy cells continue to function normally, protected against the painful side-effects of the medication.

Economics, Not Science, Is Researchers' Next Challenge

Prof. Margalit's drug carrier technology has already performed well in animal model studies. The next step is to apply the technology to humans. "Economics is the hold-up, not the science," explains Prof. Margalit, who is in the process of finding a pharmaceutical company to invest in the research.

Although the technology is still a decade or more from clinical trials, this promising discovery offers new hope in oncology.


'/>"/>

Contact: George Hunka
ghunka@aftau.org
212-742-9070
American Friends of Tel Aviv University
Source:Eurekalert  

Related medicine news :

1. Micro-Bubble Echo Contrast Procedures Continue to Rebound in October 2008
2. VIDEO from Medialink and Philips: Microbubbles Developed to Administer Medications That Fight Cancer and Reduce Side Effects
3. Cancer cells spread by releasing bubbles, according to an MUHC study
4. Wisconsin First State in Nation to Screen Newborns for Bubble Boy Disease
5. OHSU vaccine research targets HIV in the slower, early stage of infection
6. Nanoparticle smart bomb targets drug delivery to cancer cells
7. NHHF Scholarship Program Targets Growing Demand for Diversity Among Health Care Professionals
8. New Institute Targets Brain Tumor Survival
9. New institute targets brain tumor removal
10. Engineered virus targets and kills apparent cancer stem cells in neuroblastoma
11. New Vitamin Targets Health Needs of Firefighters
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New 'bubble' targets only cancer cells
(Date:7/24/2017)... ... 2017 , ... The Topricin Companies, formerly Topical Biomedics, is ... natural, after-burn skin care product, Topricin After Burn Cream. , Overexposure ... conditions, including cancer. In the short term, overexposure to sun, wind and ...
(Date:7/24/2017)... Beach, California (PRWEB) , ... July 24, 2017 ... ... commercialization of autologous fat (adipose) transfer systems announces the issuance of United States ... ‘324 patent) for its adipose filtration technology. The '398 and '324 patents ...
(Date:7/24/2017)... ... July 24, 2017 , ... Sharon Kleyne, host of the ... Health on VoiceAmerica sponsored by Nature’s Tears® EyeMist® recently talked on the air about ... in China. , The article by Zidor Aldama described the situation in which Chinese ...
(Date:7/24/2017)... ... July 24, 2017 , ... A Southern California-based author has released a ... and how she has overcome them. “Forbidden Memories: A Memoir,” by author Michelle V. ... she has risen above. , In “Memories,” readers get a firsthand look at what ...
(Date:7/24/2017)... Huntingdon Valley, PA (PRWEB) , ... July 24, 2017 , ... ... wind and rain storms wreak havoc across communities and often result in massive tree ... Top 3 actions homeowners can take now including tree trimming, tree cabling and hazardous ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... -- New York City-based market research firm Kalorama Information notes seven ... From new products to new costs, to the threat of ... study, Potential Pipeline Disruptors . Among them ... 1.  Age-Driven Growth - True Impact Moment Arriving   ... the growing population and, to a more extreme extent, the ...
(Date:7/11/2017)... , July 11, 2017  Bayer has awarded grants ... countries as part of its prestigious Bayer Hemophilia Awards Program ... of Philadelphia and Uniformed Services University ... are among the winners. Grant recipients were announced last night ... Hemostasis (ISTH) 2017 Congress, Berlin, Germany . ...
(Date:7/11/2017)... 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug delivery ... Administration (FDA) has agreed to schedule an End-of-Phase II ... trial of its oral insulin capsule ORMD-0801 in the ... met primary and secondary endpoints by indicating a statistically ...
Breaking Medicine Technology: